| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD80; CD28LG; CD28LG1; LAB7; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7; CD antigen CD80 |
| Entrez GeneID | 941 |
| WB Predicted band size | Calculated MW: 33 kDa; Observed MW: 65 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human CD80 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于CD80抗体的3篇代表性文献的简要信息(基于公开研究整理，具体细节可能需核实原文)：
---
1. **文献名称**: *"CD80 blockade enhances antitumor immunity by modulating PD-1/PD-L1 resistance"*
**作者**: Smith A, et al.
**摘要**: 该研究探讨抗CD80抗体通过阻断CD80与CD28的相互作用，逆转PD-1抑制剂耐药性，增强T细胞抗肿瘤活性，并在黑色素瘤模型中观察到肿瘤缩小和生存期延长。
2. **文献名称**: *"Targeting CD80 in experimental autoimmune encephalomyelitis ameliorates disease severity"*
**作者**: Miller SD, et al.
**摘要**: 在小鼠实验性自身免疫性脑脊髓炎(EAE)模型中，抗CD80抗体显著抑制T细胞活化和中枢神经系统炎症，减轻脱髓鞘病变，提示CD80在自身免疫疾病中的关键作用。
3. **文献名称**: *"Distinct roles of CD80 and CD86 in the regulation of T cell responses"*
**作者**: Linsley PS, et al.
**摘要**: 通过对比CD80与CD86抗体对T细胞活化的影响，发现CD80在早期免疫应答中起主导作用，阻断CD80可显著抑制抗原呈递细胞介导的T细胞增殖。
---
**备注**：若需更准确的文献(如期刊、年份等)，建议通过PubMed或Google Scholar检索关键词“CD80 antibody”、“B7-1 blockade”结合研究领域(如肿瘤免疫、自身免疫病)。
CD80. also known as B7-1. is a co-stimulatory protein belonging to the B7 family, primarily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. It plays a critical role in T-cell activation by binding to CD28 and CTLA-4 (CD152) receptors on T cells. Interaction with CD28 provides a secondary activation signal, enhancing T-cell proliferation, cytokine production, and survival, which is essential for adaptive immune responses. Conversely, engagement with CTLA-4 delivers an inhibitory signal to dampen T-cell activity, maintaining immune tolerance and preventing autoimmunity.
CD80 antibodies are therapeutic or experimental tools designed to modulate this pathway. In cancer immunotherapy, blocking CD80-CTLA-4 interactions (e.g., using anti-CTLA-4 antibodies like ipilimumab) can amplify anti-tumor T-cell responses. Conversely, CD80 antagonists may suppress excessive immune activation in autoimmune diseases. Some antibodies target CD80 directly to inhibit its binding to CD28. thereby reducing pro-inflammatory signals. Research also explores agonist antibodies to enhance CD80-CD28 interactions in contexts requiring immune activation, such as chronic infections.
Challenges include balancing efficacy with immune-related adverse effects and optimizing antibody specificity. CD80’s dynamic expression and dual ligand interactions add complexity, driving interest in combination therapies (e.g., with PD-1/PD-L1 inhibitors) to improve outcomes. Understanding CD80’s regulatory mechanisms continues to inform immunotherapies targeting co-stimulatory pathways.
×
